Pendal Group Ltd bought a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 25,322 shares of the company's stock, valued at approximately $309,000.
Other institutional investors have also recently made changes to their positions in the company. Cary Street Partners Investment Advisory LLC boosted its stake in Elanco Animal Health by 257.2% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,854 shares of the company's stock worth $35,000 after buying an additional 2,055 shares during the period. Signaturefd LLC lifted its holdings in shares of Elanco Animal Health by 97.4% in the 3rd quarter. Signaturefd LLC now owns 3,306 shares of the company's stock worth $41,000 after acquiring an additional 1,631 shares during the last quarter. Eisler Capital UK Ltd. purchased a new position in shares of Elanco Animal Health during the 3rd quarter worth about $46,000. UMB Bank n.a. grew its holdings in Elanco Animal Health by 26.9% during the 4th quarter. UMB Bank n.a. now owns 3,747 shares of the company's stock valued at $46,000 after purchasing an additional 795 shares during the last quarter. Finally, Eagle Bay Advisors LLC raised its position in Elanco Animal Health by 4,040.0% in the 2nd quarter. Eagle Bay Advisors LLC now owns 2,691 shares of the company's stock worth $53,000 after purchasing an additional 2,626 shares during the period.
Get
Elanco Animal Health alerts:
Elanco Animal Health Price Performance
Shares of NYSE ELAN opened at $9.09 on Friday. Elanco Animal Health Incorporated has a 52 week low of $8.68 and a 52 week high of $27.60. The business's 50 day moving average price is $11.62 and its 200 day moving average price is $12.35. The company has a quick ratio of 1.02, a current ratio of 1.93 and a debt-to-equity ratio of 0.75. The firm has a market cap of $4.47 billion, a P/E ratio of -60.60, a P/E/G ratio of 6.19 and a beta of 0.95.
Elanco Animal Health (NYSE:ELAN – Get Rating) last released its quarterly earnings data on Tuesday, February 21st. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a negative net margin of 1.74% and a positive return on equity of 7.57%. The business had revenue of $988.00 million for the quarter, compared to the consensus estimate of $980.94 million. During the same period in the prior year, the firm earned $0.21 EPS. The business's revenue for the quarter was down 11.2% on a year-over-year basis. On average, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.78 earnings per share for the current year.
Insiders Place Their Bets
In related news, CEO Jeffrey N. Simmons acquired 15,000 shares of the firm's stock in a transaction dated Friday, March 10th. The stock was acquired at an average price of $9.60 per share, with a total value of $144,000.00. Following the acquisition, the chief executive officer now directly owns 45,000 shares in the company, valued at approximately $432,000. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CEO Jeffrey N. Simmons bought 15,000 shares of the firm's stock in a transaction that occurred on Friday, March 10th. The stock was purchased at an average cost of $9.60 per share, for a total transaction of $144,000.00. Following the purchase, the chief executive officer now directly owns 45,000 shares in the company, valued at approximately $432,000. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director R David Hoover purchased 10,000 shares of the stock in a transaction that occurred on Friday, March 3rd. The shares were purchased at an average cost of $11.13 per share, for a total transaction of $111,300.00. Following the completion of the acquisition, the director now directly owns 155,000 shares of the company's stock, valued at approximately $1,725,150. The disclosure for this purchase can be found here. 6.40% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on ELAN shares. Morgan Stanley dropped their price objective on Elanco Animal Health from $20.00 to $19.00 and set an "equal weight" rating for the company in a report on Monday, January 30th. Piper Sandler lowered their target price on shares of Elanco Animal Health from $15.00 to $12.00 in a research note on Thursday, March 2nd. Finally, Barclays decreased their price objective on shares of Elanco Animal Health from $18.00 to $14.00 and set an "equal weight" rating for the company in a report on Wednesday, February 22nd. One investment analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. Based on data from MarketBeat, Elanco Animal Health currently has an average rating of "Hold" and a consensus target price of $16.50.
Elanco Animal Health Profile
(Get Rating)
Elanco Animal Health, Inc innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine.
Further Reading
- Get a free copy of the StockNews.com research report on Elanco Animal Health (ELAN)
- The Squeeze Is On For EVGo, Rally To Follow
- Is The Bottom In For RH, Or Is This Just A Stopping Point?
- Dividend King H.B. Fuller Signals Slowing In 2023
- Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
- 3 Companies That Just Started Paying Dividends
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
